Verve Therapeutics Executive Compensation Details
| Field | Detail |
|---|---|
| Company | Verve Therapeutics, Inc. |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Verve Therapeutics DEF 14A out: Executive pay details for 2024 are in, focusing on equity awards.
AI Summary
Verve Therapeutics, Inc. filed a DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, their fair value at year-end, and changes in fair value for outstanding awards. Specific details on compensation for named executive officers are provided within the Summary Compensation Table.
Why It Matters
This filing provides transparency into how Verve Therapeutics compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing disclosing executive compensation, not indicating new financial risks.
Key Numbers
- 2024 — Fiscal Year End (Compensation data pertains to this year.)
- 20250425 — Filing Date (Date the DEF 14A was filed with the SEC.)
Key Players & Entities
- Verve Therapeutics, Inc. (company) — Filer
- 201 BROOKLINE AVENUE, SUITE 601, BOSTON, MA 02215 (address) — Business and Mail Address
- 001-40489 (company_id) — SEC File Number
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is used to solicit proxies from shareholders for an upcoming annual or special meeting of security holders. It provides detailed information about matters to be voted on, including executive compensation, director elections, and other corporate actions.
What specific compensation elements are detailed in this Verve Therapeutics DEF 14A?
This filing details executive compensation, specifically focusing on equity awards, their fair value at year-end, and changes in fair value for outstanding awards for the fiscal year ending December 31, 2024.
When was this DEF 14A filing made by Verve Therapeutics?
Verve Therapeutics filed this DEF 14A on April 25, 2025.
What is the fiscal year end for Verve Therapeutics?
Verve Therapeutics' fiscal year ends on December 31.
What is the SIC code for Verve Therapeutics?
The Standard Industrial Classification (SIC) code for Verve Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Verve Therapeutics, Inc..